Rubaiyea Farrukee

Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model

Leo YY Lee, Jie Zhou, Paulina Koszalka, Rebecca Frise, Rubaiyea Farrukee, Keiko Baba, Shahjahan Miah, Takao Shishido, Monica Galiano, Takashi Hashimoto, Shinya Omoto, Takeki Uehara, Edin J Mifsud, Neil Collinson, Klaus Kuhlbusch, Barry Clinch, Steffen Wildum, Wendy S Barclay, Aeron C Hurt

Journal article  |  2021  |  PLOS PATHOGENS

Baloxavir is approved in several countries for the treatment of uncomplicated influenza in otherwise-healthy and high-risk patient..

Host Cell Restriction Factors of Paramyxoviruses and Pneumoviruses

Rubaiyea Farrukee, Malika Ait-Goughoulte, Philippa M Saunders, Sarah L Londrigan, Patrick C Reading

Journal article  |  2020  |  VIRUSES-BASEL

The paramyxo- and pneumovirus family includes a wide range of viruses that can cause respiratory and/or systemic infections in hum..

Utilising animal models to evaluate oseltamivir efficacy against influenza A and B viruses with reduced in vitro susceptibility

Rubaiyea Farrukee, Celeste Ming-Kay Tai, Ding Yuan Oh, Danielle E Anderson, Vithiagaran Gunalan, Martin Hibberd, Gary Yuk-Fai Lau, Ian G Barr, Veronika von Messling, Sebastian Maurer-Stroh, Aeron C Hurt

Journal article  |  2020  |  PLOS PATHOGENS

The neuraminidase (NA) inhibitor (NAI) oseltamivir (OST) is the most widely used influenza antiviral drug. Several NA amino acid s..

A rapid pyrosequencing assay for the molecular detection of influenza viruses with reduced baloxavir susceptibility due to PA/I38X amino acid substitutions

Paulina Koszalka, Rubaiyea Farrukee, Edin Mifsud, Dhanasekaran Vijaykrishna, Aeron C Hurt

Journal article  |  2020  |  INFLUENZA AND OTHER RESPIRATORY VIRUSES

Baloxavir marboxil is a novel endonuclease inhibitor licensed for treatment of otherwise healthy or high-risk individuals infected..

Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors

R Farrukee, J Butler, PC Reading, AC Hurt

Journal article  |  2019  |  ANTIVIRAL RESEARCH

Avian A(H7N9) infections in humans have been reported in China since 2013 and are of public health concern due to their severity a..

Characterization of Influenza B Virus Variants with Reduced Neuraminidase Inhibitor Susceptibility

R Farrukee, AE Zarebski, JM McCaw, JD Bloom, PC Reading, AC Hurt

Journal article  |  2018  |  ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment options for influenza B virus infections are limited to neuraminidase inhibitors (NAIs), which block the neuraminidase (..

Selection of multi-drug resistant influenza A and B viruses under zanamivir pressure and their replication fitness in ferrets

Ding Yuan Oh, Jacqueline Panozzo, Sophie Vitesnik, Rubaiyea Farrukee, David Piedrafita, Jennifer Mosse, Aeron C Hurt

Journal article  |  2018  |  ANTIVIRAL THERAPY

BACKGROUND: Intravenous zanamivir has been used to treat patients with severe influenza. Because the majority of cases (including ..

DC-SIGN and L-SIGN Are Attachment Factors That Promote Infection of Target Cells by Human Metapneumovirus in the Presence or Absence of Cellular Glycosaminoglycans

Leah Gillespie, Kathleen Gerstenberg, Fernanda Ana-Sosa-Batiz, Matthew S Parsons, Rubaiyea Farrukee, Mark Krabbe, Kirsten Spann, Andrew G Brooks, Sarah L Londrigan, Patrick C Reading

Journal article  |  2016  |  JOURNAL OF VIROLOGY

UNLABELLED: It is well established that glycosaminoglycans (GAGs) function as attachment factors for human metapneumovirus (HMPV),..

Influenza viruses with B/Yamagata- and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility

Rubaiyea Farrukee, Sook-Kwan Leang, Jeff Butler, Raphael TC Lee, Sebastian Maurer-Stroh, Danielle Tilmanis, Sheena Sullivan, Jennifer Mosse, Ian G Barr, Aeron C Hurt

Journal article  |  2015  |  JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

OBJECTIVES: The burden of disease due to influenza B is often underestimated. Clinical studies have shown that oseltamivir, a wide..

Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses

Rubaiyea Farrukee, Jennifer Mosse, Aeron C Hurt

Journal article  |  2013  |  EXPERT REVIEW OF ANTI-INFECTIVE THERAPY

Influenza A and B viruses cause significant morbidity and mortality worldwide each year. The neuraminidase inhibitors (NAIs) are t..